Results 11 to 20 of about 436,330 (367)
Itch and Janus Kinase Inhibitors
Acta Dermato-Venereologica, 2023 Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han +4 more
doaj +4 more sources
Janus kinase inhibitors in autoimmune bullous diseases
Frontiers in Immunology, 2023 Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang +9 more
doaj +4 more sources
Janus Kinase Inhibitors in the Treatment of Alopecia Areata [PDF]
Prague Medical Report, 2023 Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj +3 more sources
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib [PDF]
Journal of Clinical Medicine, 2023 Janus kinase inhibitors (JAKis) are the most recent new drug class to arrive to the market for rheumatoid arthritis (RA) treatment. While they have proven to be a very effective treatment option, there remains significant concern regarding the risk of ...
Robert Harrington +2 more
openalex +2 more sources
Janus Kinase Inhibitors and Cell Therapy [PDF]
Frontiers in Immunology, 2021 Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions.
Amer Assal +2 more
doaj +3 more sources
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis [PDF]
Frontiers in Pharmacology, 2023 Background: Janus kinase (JAK) inhibitors have emerged as a progressively utilized therapeutic approach for the management of rheumatoid arthritis (RA). However, the complete determination of their cardiovascular safety remains inconclusive.
Qiang‐hua Wei +7 more
openalex +2 more sources
Janus Kinase Inhibitors for Alopecia Areata
Journal of the American Academy of Dermatology, 2023 This systematic review and meta-analysis assesses outcomes from 7 randomized clinical trials, including changes in severity and adverse events, associated with use of JAK inhibitors among adults with alopecia areata.
Ming Liu +6 more
semanticscholar +4 more sources
Immunological Medicine, 2023 Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj +2 more sources
Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study [PDF]
Rheumatology, 2023 OBJECTIVES We aimed to investigate the risk of first primary cancer in patients with rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi) compared with those who received biologic disease-modifying anti-rheumatic drugs (bDMARDs) in a ...
Rasmus Westermann +6 more
openalex +2 more sources
Acta Dermato-Venereologica, 2023 The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score.
Farnam Barati Sedeh +4 more
doaj +2 more sources